A new Medicare option for weight loss drugs is coming: Here's what to know

NPR reports that millions of Medicare beneficiaries will soon gain access to discounted GLP-1 drugs (such as Wegovy and Zepbound) for weight loss, with copays as low as $50 per month starting July 1, 2026. The article is sourced from NPR, a major national outlet with a named byline (Jackie Fortiér), and appears to provide practical guidance on how the new Medicare option will function, though the full article body is not visible in metadata to assess depth of specifics. Independent corroboration from Reuters, FOX, and Medscape confirms the announcement timing and pricing structure, while sources like Smart Senior Daily flag administrative complexities and eligibility limitations that warrant reader attention. Critical readers should monitor implementation details around enrollment procedures, formulary restrictions, and whether coverage will extend beyond weight loss to diabetes management uses.